As you are aware, the Department of Health and Human Services has placed the therapeutic monoclonal antibody bebtelovimab, used to treat COVID-19 infection, on a state-administered allocation. The Ohio Department of Health will allocate supply weekly to hospitals and health systems based on case count and supply availability.
Based on estimated allocation, current usage, and supply on hand, we regret to inform you that bebtelovimab will no longer be stocked in the emergency departments until further notice.
All Kettering Health providers should utilize the “Outpatient COVID-19 Treatment Referral” process to refer patients for outpatient treatment options. Please see attached document for more details.
The Kettering Health P&T Outpatient COVID Treatment Algorithm (below) has been amended to include considerations for molnupiravir in an effort to conserve bebtelovimab for patients who are contraindicated to other options (ie. drug interactions, symptom onset, or pregnancy/pregnancy potential). The NIH COVID-19 Treatment Guidelines considers both bebtelovimab and molnupiravir “alternative therapies” to the preferred therapy, Paxlovid.
